Entry Point Capital, LLC Mirum Pharmaceuticals, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MIRM
# of Institutions
173Shares Held
54.2MCall Options Held
96.1KPut Options Held
54.8K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.5MShares$267 Million13.09% of portfolio
-
Janus Henderson Group PLC London, X04.99MShares$205 Million0.09% of portfolio
-
Bvf Inc San Francisco, CA4.37MShares$180 Million4.57% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.61MShares$148 Million2.18% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$133 Million0.0% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.51B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...